Mr. Chair, I am pleased to answer the question. It's a good question. This will involve a lot of work by a lot of different organizations, in fact, and different parties.
What has emerged in the meeting hosted by the Nuclear Energy Agency in Paris is a necessity for different parts of this industry or sector to collaborate on contingency planning. That includes the reactor owners, for example, who have already, including AECL, now been collaborating more closely in a group with European reactors to try to coordinate reactor schedules. That has already started. They need to further that work and ensure that indeed they are properly coordinated with respect to planned outages.
It also concerns the medical community itself, which through the nuclear medicine societies in Canada and internationally is now agreed on the need to come together, share best practices on how to address shortages, how to ensure that there's proper triage and priorities, and so forth. This is going to continue. Indeed, they have a meeting of the international association in Toronto in June, where this is going to be on the agenda.
One that is continuing as well and that is important in the mix is the private industry group of players who are in the middle here, who are distributors. More work needs to be done with that industry to ensure that in a situation of shortage the isotopes are shipped efficiently. This work includes the regulators as well who have to work on this—nuclear regulators, but also transport regulators, for example. What was agreed in Paris as well is that there would be a working group convened under the auspices of the NEA to try to coordinate all this. This working group, we expect, will be struck at a meeting in late April.
I cannot give you a specific timeline to arrive at a final product, but these are some of the timelines, and certainly the working group will be important in trying to bring this all together.